Perrigo Announces FDA Final Approval Of Betamethasone Valerate FoamPerrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.

More From CBS Detroit

Best Christmas Light Displays
Best Holiday Drink Ideas
Top Hidden Destinations

Watch & Listen